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Microglia and astrocytes play important roles in mediating the immune processes and nutritional support in the central
nervous system (CNS). Neuroinﬂammation has been indicated in the progression of neurodegenerative diseases Alz-
heimer’s disease (AD) and Parkinson’s disease (PD). Chronic neuroinﬂammation with sustained activation of microglia and
astrocytes may aﬀect white matter tracts and disrupt communication between neurons. Recent studies indicate astrogliosis
may inhibit remyelination in demyelinating disorders such as multiple sclerosis. In this study, we investigated the re-
lationship between neuroinﬂammation and myelin status in postmortem human brain tissue (n � 15 including 6 AD, 5 PD,
and 4 age-matched, neurologically normal controls (NC)). We conducted systematic and quantitative immunohisto-
chemistry for glial ﬁbrillary acidic protein (GFAP), ionized calcium-binding adaptor molecule 1 (Iba1), amyloid beta, and
highly phosphorylated tau (tauopathy). White matter intactness was evaluated by myelin and axon staining in adjacent brain
tissue sections. Eight of 15 cases (4 AD, 3 PD, and 1 NC) showed increased immunoreactivity for microglia and astrocytes in
the white matter that connects striatum and cortex. Quantitative analysis of these 8 cases showed a signiﬁcant negative
correlation between GFAP (but not Iba-1) and myelin (but not axon) staining in white matter (r2 � 0.78, p< 0.005). Tau, but
not amyloid beta plaques, is signiﬁcantly higher in AD vs. PD and NC. Tau burden increases with age in AD cases. +ese
observations indicate that astrocytosis in white matter is associated with loss of myelin in AD, PD, and normal aging and
that tau is a potent biomarker for AD.
1. Introduction
White matter disease is a common pathology involved in the
dementia of Alzheimer’s disease [1, 2], multiple sclerosis [3],
and cerebrovascular disease [4]. Brain white matter is
generally categorized into two types: deep and superﬁcial
white matter. Compared with deep white matter, superﬁcial
white matter undergoes later myelination and has less wraps
around the axon. +ese features render it vulnerable to
aging- or injury-related impairment [5]. Moreover,
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superﬁcial white matter has complex connectivity with
cortical ﬁbers and contributes to information processing
and integration [6]. +is disorder of superﬁcial white
matter has been implicated in cognitive dysfunction, such
as Alzheimer’s disease, schizophrenia, and Huntington’s
disease [7]. Astrocytes are the most numerous cell type in
the CNS and perform many physiological functions in this
system. +ese functions include maintaining homeostasis
at the synapse, regulation of neuronal signaling, protecting
neurons from oxidative damage, and assisting in the
formation of myelin. Astrocytes not only control pro-
liferation and migration of oligodendrocytes but also
regulate the timing of myelination [8]. Some studies
suggest that GFAP knockout mice have more extensive
dysfunction in the white matter than in the gray matter,
indicating that astrocytes play crucial roles in facilitating
and maintaining normal myelination [9]. However,
overactivated astrocytes also secrete factors associated
with the inhibition of myelination, such as transforming
growth factor (TGF-α) and bone morphogenetic protein
(BMP) 2/4 [10].
In addition, cerebral amyloid-beta (Aβ), neuroﬁbril-
lary tangles (abnormal tau), and neuroinﬂammation are all
involved in AD pathology [11]. Dysfunctional perivascular
cells also play a pathological role in neurodegenerative
diseases and cerebral vascular diseases [12]. In the current
study, we examined 15 autopsied human brains that in-
cluded 5 cases of Parkinson disease (PD), 6 cases of
Alzheimer disease (AD), and 4 cases of age-matched
cognitively normal controls (NC) using immunohisto-
chemistry (IHC) staining for GFAP and Iba1, Aβ and
phosphorylated tau, and α-SMA, as well as myelin and
axon staining. We found that cases with high GFAP ex-
pression (4 AD, 3 PD, and 1 NC) in superﬁcial white
matter have a signiﬁcantly negative correlation with my-
elin loss, whereas cases with low GFAP expression (2AD, 2
PD, and 3 NC) do not present negative correlation.
Phosphorylated tau was highly expressed and increased
with age in AD, and tau burden was signiﬁcantly higher
than Aβ in AD cases. +ese data suggest that chronic
inﬂammation-induced astrocytosis in superﬁcial white
matter might be associated with myelin impairment and
disease progression in these patients. Furthermore, it
suggests that tau is a more potent biomarker than Aβ for
aging-associated dementia in AD.
2. Materials and Methods
2.1. Cases. Postmortem human brain tissue samples in-
cluding six AD, ﬁve PD, and four age-matched cognitively
healthy controls (3 female and 12 male) were obtained
from the Charles F. and Joanne Knight Alzheimer’s Dis-
ease Research Center (AD and control cases) and the
Movement Disease Research Center (PD cases), De-
partment of Neurology, Washington University School of
Medicine (Table 1). Written consent from the participant
or the next-of-kin was obtained for brain removal, fol-
lowing local Institutional Review Board policies and
procedures at Washington University in St. Louis.
2.2. Tissue Collection, Staining, and Immunohistochemistry.
Brieﬂy, brains were removed at the time of autopsy and the
left hemispheres were ﬁxed in 10% neutral-buﬀered formalin
for 2weeks or more before samples were processed for
histology and embedded in paraﬃn. Histologic sections
were cut at 6 μm thickness and mounted on glass slides.
Histologic stains included hematoxylin and eosin, Luxol
fast blue and Cresyl echt violet (NeuronMyelinStain), and
Bielschowsky silver staining (Hitobiotec Corp. Kingsport,
TN, USA). For immunohistochemistry, all specimens
underwent heat-induced antigen retrieval (0.01M citrate
buﬀer at pH 6.0) and were immunostained by the EnVision
method. Specimens were then incubated overnight at 4°C
with rabbit monoclonal anti-GFAP antibody (1 : 250 di-
lution, Abcam Inc. MA, USA), rabbit polyclonal anti-Iba1
antibody (1 : 250 dilution, Wako Chemicals USA, Inc), and
rabbit polyclonal to alpha smoothmuscle actin antibody (1 :
100 dilution, Abcam Inc. MA, USA). Avidin-biotin
complex (VECTASTAIN® UNIVERSAL ELITE ABC KIT)was used for immunohistochemical staining of Aβ (10D5,
Elan Pharmaceuticals, San Francisco, CA, USA) and
phosphorylated tau (PHF-1, generous gift of Dr. Peter
Davies, Feinstein Institute for Medical Research, Man-
hasset, NY, USA), phosphorylated TDP-43 (Cosmo Bio
USA Inc, Carlsbad, CA, USA), phosphorylated α-synuclein
(Wako Chemicals USA Inc, Richmond, VA, USA), and PBS
without the primary antibody for a negative control.
Specimens were then incubated with horseradish peroxi-
dase-linked goat anti-rabbit or mouse secondary antibody
and ABC complex, followed by reaction with dia-
minobenzidine. No speciﬁc immunostaining was detected
in negative controls under these conditions. +e positive
signaling for GFAP and Iba1 was located in the cytoplasm,
and their positive areas and densities of myelin and axon
were analyzed by VISIOPHARM imaging analytic soft-
ware. +e severity of Lewy body pathology was assessed
using the Braak et al.’s Parkinson’s disease staging scale
[13]. Alzheimer’s disease neuropathological changes were
assessed by the Braak staging method [14, 15].
2.3. Statistical Analysis. All values are expressed as
mean ± SEM. Mann–Whitney nonparametric test and one-
way analysis of variance (ANOVA) were used to identify
signiﬁcant diﬀerences in two or multiple comparisons.
Pearson correlation coeﬃcients and two-tailed hypothesis
test were used to evaluate correlation between two vari-
ables. All analyses were performed by GraphPad Prism
software. A level of p< 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Clinical Features of 15Cases. As shown in Table 1, there
are 6 cases of AD, 5 cases of PD, and 4 cases of age-matched
neurologically normal controls, with the median age of 78
(69–93) years including 3 females and 12 males. +ere are
no signiﬁcant diﬀerence in the average age at death
(p> 0.8, Student’s t-test), postmortem interval (p> 0.19,
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Student’st-test), or brain weight (p> 0.28, Student’s t-test)
among PD, AD, and NC. Only one patient with PD had
bilateral subthalamic nucleus-deep brain stimulation.
All the white matter regions originating from these
samples were identiﬁed as superﬁcial white matter by his-
tological observation (Figure 1).
3.2. Expression of GFAP and Iba1 in the Astrocytosis Group
and Nonastrocytosis Group. +e expression of GFAP and
Iba1 was detected by immunohistochemistry staining. +e
activated astrocytes and microglia are shown in Figure 2(a).
+e quantitative expression of GFAP and Iba1, shown in
Figures 2(b) and 2(c), revealed signiﬁcantly higher expres-
sion of GFAP (but not Iba1) in the superﬁcial white matter of
the astrocytosis group compared to the nonastrocytosis
group (∗p< 0.05).
3.3. Diﬀerent Functional States ofMicrogliaWere Observed in
AD, PD, and NC Samples. Compared to cognitive intact
healthy control, more dystrophic and activated microglia
were spotted in AD and PD patients. +ese ﬁndings suggest
not only the activation but also the underlying degenerative
process of microglia contribute to pathologenesis of AD and
PD (Figure 3).
3.4. Negative Correlation between the GFAP Expression and
Myelin Density in the SuperﬁcialWhite Matter of Astrocytosis
Group (4 AD, 3 PD, and 1 NC). After classifying these cases
into two groups based on expression of GFAP in superﬁcial
white matter, the astrocytosis group which has high GFAP
expression and includes 4 AD, 3 PD, and 1 NC cases and the
nonastrocytosis group which includes 2 PD, 2 AD, and 3 NC
cases. Representative images of AD, PD, and NC patients for
GFAP, Iba1, and myelin and axonal staining are shown in
Figures 4(a) and 4(c). As shown in Figures 4(b) and 4(d), the
expression of GFAP signiﬁcantly inversely correlates with
myelin densities of superﬁcial white matter in the astrocy-
tosis group (R2 � 0.78, p � 0.003), but GFAP expression does
not correlate with myelin densities of superﬁcial white
matter in the nonastrocytosis group (R2 � 0.32, p � 0.18).
However, as shown in Figure 5(a), the expression of GFAP
does not signiﬁcantly correlate with axon density in the
astrocytosis group (R2 � 0.0007, p � 0.35) nor in the non-
astrocytosis group (R2 � 0.33, p � 0.18), which suggest that
astrocyte may also contribute axon generation in white
matter. Although a high but not signiﬁcant expression of
Iba1 was detected in the astrocytosis group compared to the
nonastrocytosis group, the expression status of Iba1 does not
correlate with myelin or axon densities whether in the
astrocytosis group or the nonastrocytosis group
(Figures 5(c)–5(f)).
+e expression of GFAP and Iba1 in diﬀerent regions of
6 cases of AD, 5 cases of PD, and 4 cases of age-matched
cognitively intact controls.
We also analyzed the expression of GFAP and Iba1 in
superﬁcial white matter, cortical gray matter, and striatum in
these patients (6 AD, 5 PD, and 4 NC). As shown in
Figures 6(a)–6(h), there is no signiﬁcant diﬀerences in ex-
pression of GFAP and Iba1 in AD, PD, and NC groups in
diﬀerent regions (p> 0.05), probably due to small sample
limitation. Furthermore, we analyzedmyelin and axon status
in superﬁcial white matter, there is no signiﬁcant diﬀerences
except mild decline of myelin sheath observed in PD
patients.
3.5. Tauopathy and Pericyte Status in 6 Cases of AD, 5 Cases of
PD, and 4 Cases of Age-Matched Cognitively Intact Controls.
Hyperphosphorylated tau was identiﬁed by labeling with a
PHF mouse monoclonal antibody, and tau was found to be




















84 F 67 0 Inanition 1190 8 5 0 2 PD
87 M 72 0 Inanition 1300 7.7 5 1 1 PD
73 M 58 0 Unknown 1500 52 5 1 2 PD
86 M 63 0 Inanition 1270 15 4 1 2 PD
76 M 66 75 Myocardial infarction 1400 40.5 5 0 1 PD
83 F 69 0 Inanition 900 10.5 0 5 5 AD
93 M 81 0 Inanition 1450 16 0 5 6 AD
85 M 75 0 Inanition 1130 16.5 0 5 5 AD
76 M 67 0 Inanition 1384 28 0 4 6 AD
75 M 67 0 Myocardial infarction 1430 6.5 0 3 3 AD
69 M 60 0 Non-Hodgkin’slymphoma 1350 21 0 4 6 AD
78 M N/A 0 Pneumonia 1220 14 0 0 1 NC
78 M N/A 0 Metastatic prostate cancer 1208 87 0 0 1 NC
78 F N/A 0 Duodenal cancer 1290 15.7 0 0 2 NC
91 M N/A 0 Septicemia 1250 16 0 0 2 NC
STN-DBS, subthalamic nucleus-deep brain stimulation; PMI, postmortem interval; Braak PD, Braak Lewy body stages in Parkinson’s disease (range: 1–6);
Braak Aβ, Braak beta-amyloid plaque stage; Braak NFT, Braak neuroﬁbrillary tangle stage; PD, Parkinson’s disease; AD, Alzheimer’s disease; NC, age-
matched cognitively intact normal control.
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extensively expressed in all six AD cases. Tau was not, or
rarely, expressed in PD and NC cases. +e positive areas of
tau in AD cases were primarily localized in the gray matter
and junction between gray and white matter. Intracellular
tau expression was found to be localized in the cytoplasm of
neurons and gliocytes. Phosphorylated tau was highly
expressed in AD cases. We classiﬁed these cases into two age
groups (under 80 and over 80). Tau expression was observed
to be signiﬁcantly higher in the >80 group than in the <80
group (Figure 7). Amyloid beta (Aβ) was labeled by a 10D5
antibody, and Aβ plaque burden was found to be signiﬁ-
cantly lower than tau in these AD cases (Figure 7). Dys-
function of perivascular cells was also reported to be
involved in the neuropathological diseases, such as Alz-
heimer’s disease and multiple sclerosis. Here, we in-
vestigated pericytes status by labeling α-SMA, a speciﬁc
marker for pericytes. No perivascular cytopathology was
identiﬁed in these cases (Figure 8). However, we cannot
exclude the presence of perivascular cytopathology in other
brain regions due to our sample limitations.
4. Discussion
Chronic neuroinﬂammation, mediated by reactive as-
trocytes and activated microglia, plays an important role




Figure 1: Myelin staining in the representative AD, PD, and age-matched cognitive intact controls (NC) cases. (a, c, e) +e connected ﬁne
ﬁbers between the junction of subcortical white and gray matter from AD, PD, and NC, respectively (the bars represent a 200 μm scale; the
insets show a gross view, and the small squares indicate the zoomed regions). (b, d, f ) +e ﬁbers in the subcortical white matter from the
same AD, PD, and NC cases, respectively.+e ﬁbers are short and small in diameter, they are arranged in complex cross-linking pattern (the
bars represent a 200 μm scale).
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Figure 2: Astrocytes and microglia in the striatal tissue sections using GFAP and Iba1 antibodies. (a) Representative images of activated
astrocytes and microglia in white matter, gray matter, and striatum. e activated astrocytes showed enlarged cell bodies and enlongated
bers, while activated microglia showed meatball-like appearance with enlarged cell bodies and shortened processes. e scale bar
represents 100 μm. (b, c) e quantitative analysis of the GFAP and Iba1 expression in white matter in the astrocytosis and the non-






Figure 3: Dierent morphologies of microglia in AD, PD, and NC. (a, b) Dystrophic microglia from striatal white matter and cortex of two
AD patients which displayed twisted or fragmented processes and cell body enlargement. (c, d) Activated and dystrophic microglia from
striatum of two PD patients which showed cell body enlargement and fragmented processes. (e, f ) Resting microglia from striatum of two

































































Figure 4: GFAP, Iba1, myelin, and axon staining and correlation analysis between GFAP expression and myelin density. Left panel shows
the representative IHC images of GFAP, Iba1, myelin, and axon staining in the striatal tissue sections from AD, PD, and NC cases in the
astrocytosis (a) and the nonastrocytosis group (c). Right panel shows the correlation between GFAP expression and myelin density in the





























































































































































Figure 5: Correlation analysis between GFAP and Iba1 staining with axon and myelin densities. (a, b) e correlation between the
expression of GFAP and axon densities in the astrocytosis and nonastrocytosis group. (c, d) e correlation between the expression of Iba1
and myelin densities in the astrocytosis and nonastrocytosis group. (e, f ) e correlation between the expression of Iba1 and axon densities





















































































































































































Figure 6: Relative GFAP and Iba1 expression and myelin and axon status in PD, AD, and age-matched cognitive intact controls (NC).
(a) Expression of GFAP in the striatum. (b) Expression of GFAP in white matter. (c) Expression of GFAP in gray matter. (d) Expression of
Iba1 in the striatum. (e) Expression of Iba1 in white matter. (f ) Expression of Iba1 in gray matter. (g) Myelin status in AD, PD, and NC.




Parkinson’s disease and Alzheimer’s disease. In this study,
we assessed neuroinammation in the striatum and as-
sociated cortical gray matter and white matter from 15
postmortem human brains including 6 cases of AD, 5
cases of PD, and 4 neurologically intact age-matched
controls. Although our data suggest that there is a trend
























































Figure 7: Abnormal tau expression in AD patients. (a) Neurobrillary tangle deposition in a 75-year-old male patient. (b) Neurobrillary
tangle deposition in a 93-year-old male patient (insets represent gross image, the small squares indicate the zoomed regions, and the bars
represent a 200 μm scale). (c) Quantitative analysis of tau expression in six AD cases. (d) Quantitative analysis of tau and Aβ expression in
the gray matter of six AD cases.
(a) (b) (c)
(d) (e) (f )
(g) (h) (i)
Figure 8: Immunohistochemical staining of α-SMA in AD, PD, and age-matched cognitively normal controls (NC) cases. e positive
staining (brown color) were localized in the perivascular area (pericytes). e nucleus was stained by hematoxylin. e bars represent a
100 μm scale. (a) AD1, (b) AD2, (c) AD3, (d) PD1, (e) PD2, (f ) PD3, (g) NC1, (h) NC2, (i) NC3.
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that AD cases (with high burden of beta amyloid and tau)
have more neuroinﬂammation than PD and control cases,
we found no signiﬁcant diﬀerences for activation and
proliferation of astrocytes and microglia either in cortical
gray matter, superﬁcial white matter, or striatum among
PD, AD, and controls. +is is consistent with translocator
protein binding (TSPO) or previous peripheral benzo-
diazepine receptor (PBR) quantitative autoradiography
studies using [3H]PK11195 and [3H]PBR28 in post-
mortem frozen human brains; TSPO binding density was
found to be not signiﬁcantly diﬀerent among AD (n � 7),
dementia with Lewy bodies (DLB) disease (n � 5), or
cognitively intact age-matched controls (n � 8) in these
brain regions [16]. However, some cases in the current
study (4 AD, 3 PD, and 1 NC) showed a signiﬁcantly
higher expression of GFAP in the superﬁcial white matter
(>0.5 positive staining area), in comparison to the other
cases (2 AD, 2 PD, and 3 NC) (<0.4 positive staining area).
Based on this diﬀerence, we classiﬁed these cases into two
groups: astrocytosis (4 AD, 3 PD, and 1 NC) and non-
astrocytosis (2 AD, 2 PD, and 3 NC). Staining of myelin
and axon was performed to investigate the relationships
between the activation of glia cells (astrocyte and
microglia) and neurodegeneration, as reﬂected by axonal
and myelin integrity in the subcortical-striatal superﬁcial
white matter. We found that GFAP expression signiﬁ-
cantly negatively correlated with myelin density in su-
perﬁcial white matter in the astrocytosis group, but not in
the nonastrocytosis group. In contrast, Iba1 staining did
not correlate signiﬁcantly with myelin density in either
group.
Myelin sheath can boost neural transduction via the
node of Ranvier by insulating nerve cell axons in the central
and peripheral nervous systems. Damaged myelin sheath
could be a biomarker for the early-stage axon degeneration.
It has been reported that demyelination could induce axon
abnormalities by reducing axon caliber, abnormal neuro-
ﬁlament distribution, and increasing mitochondria num-
ber [17–19]. However, a study posited that axonal
degeneration could occur independently from myelin loss
[20]. Here, we also investigated axon density in superﬁcial
white matter and evaluated its association with the ex-
pression of GFAP or Iba1 and myelin densities in super-
ﬁcial white matter. Myelin density did not signiﬁcantly
correlate with axon density in all 15 cases (data not shown),
nor did axon density signiﬁcantly correlate with GFAP or
Iba1 expression.
Tau pathology has been a hallmark of Alzheimer’s dis-
eases (AD). Tau exists as monomers, paired helical ﬁaments
(PHFs), and straight ﬁlaments in AD [21]. Here, we in-
vestigated tau status by labeling with a PHF antibody in the
striatal sections of AD, PD, and NC cases. Phosphorylated
tau was highly expressed in all AD patients, especially in the
age >80 group, compared to PD and NC cases. Furthermore,
we also conducted amyloid beta immunohistochemistry in
the adjacent sections of all cases. No concurrent expression
of phosphorylated tau and amyloid beta was found in these
cases except for one case, 83-year-old female. +is case had a
decent expression of amyloid beta in the gray matter area.
+e overall expression of amyloid beta was signiﬁcantly
lower compared to phosphorylated tau in all AD cases. No
obvious expression of amyloid beta was observed in all PD
and NC cases. +ese data support the hypothesis that tau
pathology is independent of amyloid beta in the neurode-
generative diseases and that neuroﬁbrillary tangles (tauop-
athy) are a better biomarker for predicting cognitive
impairment in Alzheimer’s diseases.
Pericytes, the perivascular-specialized smooth muscle
cells, have multiple pathological functions in the brain.
Interactions between pericytes and endothelial cells are
important for the remodeling and maintenance of the
vascular system. Pericytes also regulate the neurotransmitter
transport and vascular permeability. Dysfunction of peri-
cytes is involved in neuropathological diseases, such as
hypertension, diabetic retinopathy, and Alzheimer’s diseases
[12]. Here, in this study, we also evaluated pericyte status by
α-SMA staining. No obvious perivascular cytopathology was
observed in the cases we studied.
Patients with neurodegeneration disease often have
damage in the white matter, which is composed of axonal
ﬁbers interconnecting neurons in the brain [22]. White
matter damage, which includes demyelination and in-
ﬂammation, is associated with cognitive dysfunction and is
one of the most important factors in the complex etiology of
AD [23, 24]. Our study suggests that chronic activation of
astrocytes and microglia may contribute to myelin sheath
loss and nerve ﬁber degeneration. Abnormal tau was highly
expressed in AD compared to PD and NC. Neuroﬁbrillary
tangles deposition is independent of plaques formation in
the course of AD. No dysfunctional pericytes were observed
in AD, PD and NC cases. Taken together, reactive astrocytes
may produce toxic eﬀects on myelin sheath and abnormal
tau has a better correlation with AD dementia than amyloid
beta.
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